Companies:
50,403
Total Market Cap:
145625271842349.07
Global Rank
#370
Country Rank
#36
Market Cap
60.33 B
Price
9.07
Change (%)
1.55%
Volume
63.77 M
Jiangsu Hengrui Medicine's latest marketcap:
60.33 B
As of 08/23/2025, Jiangsu Hengrui Medicine's market capitalization has reached $60.33 B. According to our data, Jiangsu Hengrui Medicine is the 370th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 60.33 B |
| Revenue (ttm) | 4.21 B |
| Net Income (ttm) | 1.03 B |
| Shares Out | 6.63 B |
| EPS (ttm) | 0.16 |
| Forward PE | 42.10 |
| Ex-Dividend Date | 05/23/2025 |
| Earnings Date | 08/21/2025 |
Market Cap Chart
Data Updated: 08/23/2025
Jiangsu Hengrui Medicine's yearly market capitalization.
Jiangsu Hengrui Medicine has seen its market value grow from ¥56.37 B to ¥432.34 B since 2014, representing a total increase of 666.97% and an annual compound growth rate (CAGR) of 21.09%.
| Date | Market Cap(¥) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/23/2025 | ¥432.34 B | $60.33 B | 46.09% | 370 |
| 12/31/2024 | ¥291.86 B | $39.97 B | 1.48% | 489 |
| 12/29/2023 | ¥287.6 B | $40.51 B | 17.03% | 442 |
| 12/30/2022 | ¥245.74 B | $35.61 B | -23.94% | 460 |
| 12/31/2021 | ¥323.08 B | $50.84 B | -45.4% | 371 |
| 12/31/2020 | ¥591.75 B | $90.65 B | 53.53% | 150 |
| 12/31/2019 | ¥385.43 B | $55.35 B | 98.44% | 221 |
| 12/28/2018 | ¥194.23 B | $28.24 B | 0.12% | 401 |
| 12/29/2017 | ¥193.99 B | $29.8 B | 82.26% | 425 |
| 12/30/2016 | ¥106.44 B | $15.33 B | 10.75% | 684 |
Company Profile
About Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd. is a leading pharmaceutical company specializing in the research, development, manufacturing, and commercialization of drugs in China and internationally.
Key Focus Areas
- Drug Development: Antineoplastic drugs, surgery medications, and treatments for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology.
- Product Portfolio: Analgesia and anesthesia products, as well as contrast agents.
Additional Services
- Technical consulting and training
- Investment advisory services
- Technology development and project management
- Import and export of pharmaceutical products
Founded: 1970
Headquarters: Lianyungang City, China
Frequently Asked Questions
-
What is Jiangsu Hengrui Medicine's (SHA-600276) current market cap?As of 08/23/2025, Jiangsu Hengrui Medicine (including the parent company, if applicable) has an estimated market capitalization of $60.33 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Jiangsu Hengrui Medicine (SHA-600276) rank globally by market cap?Jiangsu Hengrui Medicine global market capitalization ranking is approximately 370 as of 08/23/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.